Native Mass Spectrometry Reveals Binding Interactions of SARS-CoV-2 PLpro with Inhibitors and Cellular Targets

被引:0
|
作者
James, Virginia K. [1 ]
Godula, Rianna N. [2 ]
Perez, Jessica M. [2 ]
Beckham, Josh T. [3 ]
Butalewicz, Jamie P. [1 ]
Sipe, Sarah N. [1 ]
Huibregtse, Jon M. [2 ]
Brodbelt, Jennifer S. [1 ]
机构
[1] Univ Texas Austin, Dept Chem, Austin, TX 78712 USA
[2] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA
[3] Univ Texas Austin, Freshman Res Initiat, Austin, TX 78712 USA
来源
ACS INFECTIOUS DISEASES | 2024年 / 10卷 / 10期
基金
美国国家卫生研究院;
关键词
ultraviolet photodissociation; mass spectrometry; SARS-CoV protease; PLpro; inhibitor; protein-protein interactions; CROSS-LINKING; DISTANCE RESTRAINTS; PAPAIN-LIKE; PROTEIN; PR-619;
D O I
10.1021/acsinfecdis.4c00444
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Here we used native mass spectrometry (native MS) to probe a SARS-CoV protease, PLpro, which plays critical roles in coronavirus disease by affecting viral protein production and antagonizing host antiviral responses. Ultraviolet photodissociation (UVPD) and variable temperature electrospray ionization (vT ESI) were used to localize binding sites of PLpro inhibitors and revealed the stabilizing effects of inhibitors on protein tertiary structure. We compared PLpro from SARS-CoV-1 and SARS-CoV-2 in terms of inhibitor and ISG15 interactions to discern possible differences in protease function. A PLpro mutant lacking a single cysteine was used to localize inhibitor binding, and thermodynamic measurements revealed that inhibitor PR-619 stabilized the folded PLpro structure. These results will inform further development of PLpro as a therapeutic target against SARS-CoV-2 and other emerging coronaviruses.
引用
收藏
页码:3597 / 3606
页数:10
相关论文
共 50 条
  • [41] Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
    Garnsey, Michelle R.
    Robinson, Matthew C.
    Nguyen, Luong T.
    Cardin, Rhonda
    Tillotson, Joseph
    Mashalidis, Ellene
    Yu, Aijia
    Aschenbrenner, Lisa
    Balesano, Amanda
    Behzadi, Amin
    Boras, Britton
    Chang, Jeanne S.
    Eng, Heather
    Ephron, Andrew
    Foley, Tim
    Ford, Kristen K.
    Frick, James M.
    Gibson, Scott
    Hao, Li
    Hurst, Brett
    Kalgutkar, Amit S.
    Korczynska, Magdalena
    Lengyel-Zhand, Zsofia
    Gao, Liping
    Meredith, Hannah R.
    Patel, Nandini C.
    Polivkova, Jana
    Rai, Devendra
    Rose, Colin R.
    Rothan, Hussin
    Sakata, Sylvie K.
    Vargo, Thomas R.
    Qi, Wenying
    Wu, Huixian
    Liu, Yiping
    Yurgelonis, Irina
    Zhang, Jinzhi
    Zhu, Yuao
    Zhang, Lei
    Lee, Alpha A.
    SCIENCE ADVANCES, 2024, 10 (35):
  • [42] Identification and characterization of aurintricarboxylic acid as a potential inhibitor of SARS-CoV-2 PLpro
    Arya, Rimanshee
    Prashar, Vishal
    Kumar, Mukesh
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 230
  • [43] Immune characterization and profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-CoV-2 oncogenesis mechanism
    Policard, Martine
    Jain, Sidharth
    Rego, Samantha
    Dakshanamurthy, Sivanesan
    VIRUS RESEARCH, 2021, 301
  • [44] 6-Thioguanine blocks SARS-CoV-2 replication by inhibition of PLpro
    Swaim, Caleb D.
    Dwivedi, Varun
    Perng, Yi-Chieh
    Zhao, Xu
    Canadeo, Larissa A.
    Harastani, Houda H.
    Darling, Tamarand L.
    Boon, Adrianus C. M.
    Lenschow, Deborah J.
    Kulkarni, Viraj
    Huibregtse, Jon M.
    ISCIENCE, 2021, 24 (09)
  • [45] Repurposing FDA-Approved Drugs as Potential Inhibitors of SARS-CoV-2 PLpro: A Comprehensive Computational Study
    Metwaly, Ahmed M.
    Elkaeed, Eslam B.
    Alsfouk, Aisha A.
    Ibrahim, Ibrahim M.
    Soliman, Omar A.
    Elkady, Hazem
    Eissa, Ibrahim H.
    JOURNAL OF COMPUTATIONAL BIOPHYSICS AND CHEMISTRY, 2024, 23 (09): : 1209 - 1231
  • [46] Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants
    Raghu, Deepa
    Hamill, Pamela
    Banaji, Arpitha
    McLaren, Amy
    Hsu, Yu-Ting
    JOURNAL OF PHARMACEUTICAL ANALYSIS, 2022, 12 (01) : 58 - 64
  • [47] Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants
    Deepa Raghu
    Pamela Hamill
    Arpitha Banaji
    Amy McLaren
    Yu-Ting Hsu
    JournalofPharmaceuticalAnalysis, 2022, 12 (01) : 58 - 64
  • [48] Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
    Klemm, Theresa
    Ebert, Gregor
    Calleja, Dale J.
    Allison, Cody C.
    Richardson, Lachlan W.
    Bernardini, Jonathan P.
    Lu, Bernadine G. C.
    Kuchel, Nathan W.
    Grohmann, Christoph
    Shibata, Yuri
    Gan, Zhong Yan
    Cooney, James P.
    Doerflinger, Marcel
    Au, Amanda E.
    Blackmore, Timothy R.
    van der Heden van Noort, Gerbrand J.
    Geurink, Paul P.
    Ovaa, Huib
    Newman, Janet
    Riboldi-Tunnicliffe, Alan
    Czabotar, Peter E.
    Mitchell, Jeffrey P.
    Feltham, Rebecca
    Lechtenberg, Bernhard C.
    Lowes, Kym N.
    Dewson, Grant
    Pellegrini, Marc
    Lessene, Guillaume
    Komander, David
    EMBO JOURNAL, 2020, 39 (18):
  • [49] The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery
    Ziyang Fu
    Bin Huang
    Jinle Tang
    Shuyan Liu
    Ming Liu
    Yuxin Ye
    Zhihong Liu
    Yuxian Xiong
    Wenning Zhu
    Dan Cao
    Jihui Li
    Xiaogang Niu
    Huan Zhou
    Yong Juan Zhao
    Guoliang Zhang
    Hao Huang
    Nature Communications, 12
  • [50] Structures of SARS-CoV-2 RNA-Binding Proteins and Therapeutic Targets
    Khan, Muhammad Tahir
    Irfan, Muhammad
    Ahsan, Hina
    Ahmed, Abrar
    Kaushik, Aman Chandra
    Khan, Anwar Sheed
    Chinnasamy, Sathishkumar
    Ali, Arif
    Wei, Dong-Qing
    INTERVIROLOGY, 2021, 64 (02) : 55 - 68